Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Recurrence 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lymphatic Diseases 1Leukemia, Myeloid, Acute 1Immunoproliferative Disorders 1Immune System Diseases 1Hematologic Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 23Cisplatin 22durvalumab 13pembrolizumab 8Oxaliplatin 7Capecitabine 7Fluorouracil 6Leucovorin 5Bevacizumab 5lenvatinib 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4Nivolumab 3Liquid Biopsy 3Injections 3Folfox protocol 3zanidatamab 2trifluridine tipiracil drug combination 2tremelimumab 2tislelizumab 2ivosidenib 2futibatinib 2apatinib 2Trastuzumab 2Taxes 2Irinotecan 2Immune Checkpoint Inhibitors 2Drug Therapy 2Carboplatin 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Biliary Tract Neoplasms × CA-4948 × Clear all
NCT07107750 2026-04-03

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Washington University School of Medicine

Phase 1 Recruiting
48 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡